The patient, a 22-year-old woman, was admitted for evaluation of the cause of recent onset of severe headaches. Her cerebrospinal fluid was grossly bloody, and angiography revealed an aneurysm of the middle cerebral artery. We used the following instruments to measure total protein in serum in duplicate: the "Astra 8" (Beckman Instruments, Inc., Clinical Instruments the values for apparent total protein by 35%). The Parallel also showed falsely increased results: at a dextran concentration as low as 2 g/L, total protein values were 13% greater than those in the control; at 10 g/L, the value for apparent total protein was 136% of the control value. In contrast, dextran had a negative interference in the aca, but this effect did not become noticeable until the dextran concentration exceeded 5 g/L. With the aca, dextran at 10 g/L lowered the results for total protein by 16% in comparison with the control; at 30 g/L the decrease was about 78%.
falselyhighresultswhen the dextranconcentrationexceeded 2 g/L. The aca total protein procedure could be protected from the interferenceby dextran concentrationsup to 30 g/L by injecting 0.4-0.8 mL of ethylene glycol directly into the reagent pack before sampling. However, we could not eliminate the interference with the Parallel procedure by any simple means; we thus recommend that it not be used for measuring total protein in serum samples from patients who are being treated with dextran. 
Materials and Methods
The patient, a 22-year-old woman, was admitted for evaluation of the cause of recent onset of severe headaches. Her cerebrospinal fluid was grossly bloody, and angiography revealed an aneurysm of the middle cerebral artery. her factor Vifi coagulant activity was only 16% of normal. She had no history of clotting abnormalities, sothis deficiency was ascribed to the therapy with dextran. Postoperatively, her concentrations of total protein in serum were high, which we investigated. After dextran therapy was stopped, values for factor Vifi coagulant activity and total protein returned to normal.
Serum sampled from the patient at various times during her hospitalization was stored at -20 #{176}C until analyzed.
To prepare samples containing concentrations of dextran 40 ranging from 0 to 30 g/L, we mixed different volumes of a 100 g/L solution of "Rheomacrodex"
Piscataway, NJ 08854) with a constant volume of a pooled specimen of patients' serum. Isotonic saline (NaCl, 9 g/L)
made up the difference in volume, ensuring that the total proteinconcentration of all the samples was the same.
We used the following instruments to measure total protein in serum in duplicate: the "Astra 8" (Beckman Instruments, Inc., Clinical Instruments greater than those in the control; at 10 g/L, the value for apparent total protein was 136% of the control value. In contrast, dextran had a negative interference in the aca, but this effect did not become noticeable until the dextran concentration exceeded 5 g/L. With the aca, dextran at 10 g/L lowered the results for total protein by 16% in comparison with the control; at 30 g/L the decrease was about 78%.
We retrospectively measured total protein in many of the serum samples collected during the course of the patient's The anvw indicatesthe daywhen dextrantherapywas discontinued. Symbolsas In Fig. 1 er, the composition of the reagents, the modes of measurement, and the response to dextran vary significantly with each procedure. The Cobas-Bio procedure includes a reagent containing 9 g of tartrate per liter. Although Flack and Woollen (7) report that, to avoid interference by dextran, tartrate concentration should be maintained at either <5 or >15 g/L, we found no appreciable effect of dextran on the assay until the dextran concentration exceeded 25 g/L-a concentration likely to be encountered during therapy (5).
Our findings contrast with those of Magid and R#{248}nsbo (5), who demonstrated that a method involving a reagent with similar composition was affected by dextran at concentrations as low as 4.6 g/L. We ascribe this lack of substantial interference with the Cobas-Bio procedure to the centrifligation of the reaction mixtures during analysis, which probably removes the interfering dextran precipitate. The manufacturer of the Astra 8 procedure would not reveal the concentration of tartrate in the total protein reagent; we speculate that the lack of interference by dextran in this procedure is due to either the presence of a proper concentration of tartrate (<5 or >15 g/L) or the measurement of the rate of change in absorbance at 545 mn. In the Ektachem 400, protein in the sample migrates into a dye-mordant layer, where it reacts with copper tartrate in a highly alkaline environment (maintained by lithium hydroxide) to produce a violet complex. The lack of interference by dextran with this procedure probably is ascribable to the very high amount of tartrate (3500g, to be hydrated by 10 j.L of serum).
Apparently, the bichromatic procedure used in the aca cannot correct for the negative interference when dextran exceeds 5 g/L. The positive interference that dextran has on the Parallel procedure is more disturbing, because misleadingly high values for total protein could potentially influence diagnostic and perhaps costly therapeutic decisions. Indeed, in the patient we studied, diagnostic procedures to rule out multiple myeloma were underway before we recognized that the total-protein values for previous specimens from this patient were falsely increased. Our experience to date with the Parallel procedure suggests that the most feasible approach to eliminate the dextran interference with this method would be to alter the composition of the reagent by including the proper amount of tartrate. Without data to document the accuracy of an improved formulation, the Parallel procedure should not be used for analysis of total protein in patients receiving dextran.
